Cellular immune response to SARS-CoV-2 in patients with primary antibody deficiencies
ConclusionsOur results documented satisfactory in vitro cellular immune response in PAD patients after booster SARS-CoV-2 vaccination. Therefore, even patients with agammaglobulinemia should benefit from vaccination due to the apparent induction of cell-mediated immunity, which, together with IgRT, grants comprehensive protection against the pathogen.
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
More News: Allergy & Immunology | Grants | Pfizer | SARS | Study | Vaccines | X-Linked Agammaglobulinemia (XLA)